Uli C. Broedl - Concepedia

Author

Uli C. Broedl

Boehringer Ingelheim (Germany)ORCID

Also Known As

Hans J. Woerle, U. C. Broedl, U.C. Broedl, Uli Broedl, Uli C Broedl, Uli C. Broedl, Uli C. Broedl MD

146

Publications

31.9K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)Boehringer Ingelheim (Norway)University of Toronto Boehringer Ingelheim (France)

About

Uli C. Broedl is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacology, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	30	2.9K
2	Health Sciences	3	3	206
3	Engineering	2	2	73
4	Natural Sciences	2	2	64
5	Public Health	2	2	100

Uli C. Broedl

Publications

28.7K

Citations

H-Index

Page 1

	Year	Citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, Christoph Wanner, John M. Lachin, New England Journal of Medicine	2015	11.6K
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, New England Journal of Medicine	2016	3.5K
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, Circulation	2013	1.3K
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Journal of Clinical Investigation	2014	1.1K
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial Anthony Barnett, Ambrish Mithal, Jenny Manassie, The Lancet Diabetes & Endocrinology Diabetes ManagementInsulin ManagementDiabetesChronic Kidney DiseasePharmacology	2014	567
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes Robert Ćhilton, I. Tikkanen, Christopher P. Cannon, Diabetes Obesity and Metabolism	2015	494
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, Circulation	2017	462
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, Cardiovascular Diabetology	2014	458
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Diabetes Care	2014	454
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial Michael Roden, Jianping Weng, Jens Eilbracht, The Lancet Diabetes & Endocrinology Diabetes ManagementCardiovascular DiseaseMedicineDiabetesActive Comparator	2013	438

Page 1